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Abstract
Background: Many patients suffering from depressive disorders are refractory to treatment with currently available 
antidepressant medications, while many more exhibit only a partial response. These factors drive research to discover new 
pharmacological approaches to treat depression. Numerous studies demonstrate evidence of inflammation and elevated 
oxidative stress in major depression. Recently, major depression has been shown to be associated with elevated levels of DNA 
oxidation in brain cells, accompanied by increased gene expression of the nuclear base excision repair enzyme, poly(ADP-
ribose) polymerase-1. Given these findings and evidence that drugs that inhibit poly(ADP-ribose) polymerase-1 activity have 
antiinflammatory and neuroprotective properties, the present study was undertaken to examine the potential antidepressant 
properties of poly(ADP-ribose) polymerase inhibitors.
Methods: Two rodent models, the Porsolt swim test and repeated exposure to psychological stressors, were used to test the 
poly(ADP-ribose) polymerase inhibitor, 3-aminobenzamide, for potential antidepressant activity. Another poly(ADP-ribose) 
polymerase inhibitor, 5-aminoisoquinolinone, was also tested.
Results: Poly(ADP-ribose) polymerase inhibitors produced antidepressant-like effects in the Porsolt swim test, decreasing 
immobility time, and increasing latency to immobility, similar to the effects of fluoxetine. In addition, 3-aminobenzamide 
treatment increased sucrose preference and social interaction times relative to vehicle-treated control rats following repeated 
exposure to combined social defeat and unpredictable stress, mediating effects similar to fluoxetine treatment.
Conclusions: The poly(ADP-ribose) polymerase inhibitors 3-aminobenzamide and 5-aminoisoquinolinone exhibit 
antidepressant-like activity in 2 rodent stress models and uncover poly(ADP-ribose) polymerase as a unique molecular target 
for the potential development of a novel class of antidepressants.
Keywords: major depression, antidepressant, PARP inhibitor
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Introduction
Conditions of elevated oxidative stress and inflammation are 
proposed to play a role in the pathophysiology of major depres-
sive disorder (MDD) as well as several psychiatric, neurologi-
cal, and medical diseases (Van Gaal et al., 2006; Maes et al., 
2011; Haroon et al., 2012; Leza et al., 2015; Miller et al., 2016; 
Swardfager et al., 2016). Since oxidative stress can drive inflam-
mation and vice versa, it is likely that these 2 pathophysiological 
features of MDD are interrelated. Evidence of oxidative stress 
conditions in MDD include numerous demonstrations in MDD 
patients of reduced plasma concentrations of free radical scav-
engers and elevated levels of oxidation products, including oxi-
dized or damaged DNA (Forlenza and Miller, n.d.; Bilici et al., 
2001; Owen et al., 2005; Simon et al., 2006; Yager et al., 2010; 
Maes et al., 2011). Likewise, numerous researchers have reported 
elevated indices of inflammation in MDD, including C-reactive 
protein, cytokines, and IgG antibodies (Howren et al., 2009; Maes 
et al., 2011; Haapakoski et al., 2015). These findings raise the pos-
sibility that drugs that prevent inflammation and/or oxidative 
damage may have antidepressant efficacy (Anderson and Maes, 
2014; Miller et al., 2016).
Recently, elevated levels of nucleic acid oxidation have been 
observed in brain white matter (Szebeni et al., 2016) and the hip-
pocampus (Che et  al., 2010) from MDD brain donors compared 
with normal control brain donors. Both white matter and the hip-
pocampus contain cells that are uniquely susceptible to oxidative 
stress. In the hippocampus, these cells include CA1 pyramidal 
neurons (Wang and Michaelis, 2010). In white matter, myelinat-
ing oligodendrocytes are the predominant cellular residents, and 
these cells are normally susceptible to oxidative damage because 
of their high rate of metabolism, high levels of iron, and rela-
tively low levels of antioxidant enzyme expression (Kim and Kim, 
1991; Connor and Menzies, 1996; Thorburne and Juurlink, 1996; 
Juurlink et  al., 1998). Other indicators of oxidative damage to 
brain white matter in MDD include shortened telomeres, reduced 
gene expression of antioxidant enzymes, and upregulation of the 
gene expression of DNA base excision repair enzymes, poly(ADP-
ribose) polymerase-1 (PARP1) and oxoguanine glycosylase, in 
white matter oligodendrocytes from MDD donors (Szebeni et al., 
2014, 2016). Interruption of the damaging effects of oxidation in 
white matter or other susceptible brain regions has the potential 
to provide therapeutic benefit in the treatment of MDD.
The observation of upregulated PARP1 gene expression in 
MDD (Szebeni et al., 2016) is particularly interesting given the 
role of this enzyme in numerous cellular functions. The activity 
of PARP1 is activated by strand breaks in DNA such as result from 
oxidative attack of DNA bases. PARP1 uses NAD+ as a substrate 
to attach poly(ADP-ribose) (PAR) polymers to proteins, including 
PARP1 itself and other nuclear proteins, including histones (De 
Vos et  al., 2012). Through PARylation and also protein-protein 
interactions, PARP1 participates in several molecular pathways, 
including DNA repair, chromatin remodeling, and activation of 
NF-κB (Gibson and Kraus, 2012). Drugs that inhibit PARP1 activ-
ity have therapeutic benefit in the treatment of certain cancers, 
because they increase the lethality of DNA damaging anti-can-
cer treatments (De Vos et al., 2012). Interestingly, PARP inhibition 
or PARP1 knockout delivers antiinflammatory and/or neuropro-
tective effects in a variety of experimental disease conditions, 
including chronic asthma (Zaffini et al., 2016), myocardial infarc-
tion (Wayman et al., 2001), stress-evoked immuno-compromise 
(Drazen et al., 2001), traumatic brain injury (Besson et al., 2003), 
and cerebral ischemia (Gerace et al., 2012). The finding of ele-
vated DNA oxidation and upregulation of gene expression of 
PARP1 in white matter in MDD (Szebeni et al., 2016) raises the 
possibility that pharmacological inhibition of PARP1 could inter-
fere with pathological processes that contribute to this disorder. 
In light of this possibility, we (Szebeni et al., 2016) and others 
(Liu et al., 1996; Sigwalt et al., 2011) have demonstrated elevated 
levels of DNA oxidation in rat brain following repeated expo-
sure to stress, showing that stressed rats may be useful for the 
study of the behavioral effects of drugs that reverse downstream 
effects of oxidative damage to brain cells. Since DNA oxidation 
activates PARP1, which activates NF-κB and downstream inflam-
mation, it seems reasonable to predict that PARP inhibitors may 
have antidepressant properties that are detectable in rodent 
stress models.
The possibility that PARP inhibitors could have therapeu-
tic utility in the treatment of MDD is strongly supported by a 
number of related studies that have not made the direct con-
nection between PARP inhibition and antidepressant action. 
Though chiefly prescribed as an antibiotic, numerous studies 
have shown that minocycline mediates a beneficial neuropro-
tective effect with efficacy for a wide variety of diseases (Chen 
et  al., 2000; Tikka and Koistinaho, 2001; Nirmalananthan and 
Greensmith, 2005). Interestingly, minocycline is a high affin-
ity inhibitor of PARP-1; subsequent comparison across several 
tetracycline derivatives found a strong correlation between 
PARP-1 binding and neuroprotective potency (Alano et al., 2006). 
Furthermore, antidepressant effects of minocycline have been 
anecdotally observed in humans as well as in many studies 
using rodent models (Molina-Hernández et al., 2008; O’Connor 
et al., 2009; Arakawa et al., 2012; Saeedi Saravi et al., 2016). In a 
study of inflammation and its behavioral consequences, treat-
ment of rats with the PARP inhibitor 3-aminobenzamide (3-AB) 
reversed depressive effects caused by lipopolysaccharide injec-
tion (Sriram et al., 2015). However, this sickness-based model for 
depression arguably remains etiologically distant from causes of 
MDD in humans (Stepanichev et al., 2014).
In the present study, we tested the hypothesis that PARP 
inhibition will have antidepressant activity using 2 different 
rodent models involving psychological stress: (1) a combined 
repeated social defeat and repeated unpredictable stress model, 
both models of which are used to identify antidepressant effects 
(O’Leary and Cryan, 2013) and/or used to explore the biologi-
cal effects of psychological stress in relation to posttraumatic 
Significance Statement
Currently available drugs for the treatment of depression have numerous limitations. Many depressed people do not respond 
to these drugs, and even more people experience only a partial response. There is a crucial need to find more effective and safe 
treatments for depression. The novel discovery of a class of drugs with antidepressant properties is described herein using 
standard animal models used to screen drugs for antidepressant activity. The biological properties of these drugs, called PARP 
inhibitors, is very different from existing antidepressants. Evidence also demonstrates that these drugs can boost the antidepres-
sant-like effect of a traditional antidepressant.
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stress disorder (Whitaker et  al., 2014; Borghans and Homberg, 
2015); and (2) the Porsolt swim test, commonly used to identify 
antidepressant/antianxiety drugs (O’Leary and Cryan, 2013). 
Two structurally different PARP inhibitors were tested: 3-AB and 
5-aminoisoquinolinone (5-AIQ). Both of these drugs have been 
shown to be antagonists of PARP, and both drugs have also been 
demonstrated to produce neuroprotective and/or antiinflamma-
tory actions in other disease models (Wallis et al., 1996; Hendryk 
et al., 2008; Zaffini et al., 2016). The present study demonstrates 
that the PARP inhibitors 3-AB and 5-AIQ have antidepressant-
like activity. These findings uncover PARP as a unique molecular 
target for the development of a novel class of antidepressants.
Materials and Methods
Laboratory Animals
The use of animals for this study was approved by the University 
Committee on Animal Care at East Tennessee State University. 
All rats were ordered from Envigo, Inc. Male Sprague-Dawley 
rats (225–250  g upon arrival) were used as subjects in the 
Porsolt swim test and were socially housed in groups of 2 to 3 
per cage. Rats used as “intruders” in the social defeat paradigm 
were individually housed and provided enrichment per the NIH 
Guidelines for the Care and Use of Animals. Intruder rats were 
male Sprague-Dawley rats (225–250 g). In addition, a total of 14 
female Sprague-Dawley rats weighing 175 to 199 g upon arrival 
were obtained for the social defeat paradigm, and these rats 
were socially housed for 6 days in the animal colony prior to fal-
lopian tube ligature, performed as previously described (Szebeni 
et al., 2016). Sixteen male Long-Evans hooded rats weighing 250 
to 275 g upon arrival were used as “residents” in the social defeat 
paradigm. A climate-controlled vivarium was utilized, and ani-
mals were kept on a 12-h-on/12-off light/dark cycle.
Social Defeat Stress (SDS)
SDS was induced as described previously (Covington and 
Miczek, 2001; Szebeni et  al., 2016). Briefly, Long-Evans hooded 
rats (residents) were each mated with a female (ligated) rat for a 
7-day period. On the eighth day and after removal of the female, 
an intruder rat was placed into the cage for a 5-minute period, 
and dominance was established by the resident. Defeat was pro-
duced between 9:00 am and 10:00 am daily for 10 consecutive 
days. Control rats not exposed to defeat were handled each day 
during this same period.
Chronic Unpredictable Stress (CUS)
CUS was performed after SDS on the same day but at random 
times either during the day or evening as previously described 
(Bondi et al., 2008; Szebeni et al., 2016). Different stressors were 
randomly arranged and occurred at random times during the 
light or dark cycle of each day for 10 consecutive days. All rats 
were exposed twice to each of 5 different stressors, which 
included a 30-minute restraint, a 1-hour shaking/crowding, 
10-minute cold water (18oC) swim, a 15-minute warm water 
swim (25oC), and a 24-hour tipped cage. For restraint, rats were 
placed in a restraining device made of Plexiglas restricting 
movement but allowing free respiration and air circulation. In 
the shaking-crowding procedure, 6 rats were placed in a card-
board box atop a laboratory shaker set to produce 220 back-
and-forth movements (approximately 2-in sideways deflection) 
per minute. Both warm and cold swims were accomplished 
by placing the rat in a cylindrical tank (60 cm height × 30 cm 
diameter) filled with water at a depth of 30 cm. For the tipped 
cage, the animal’s home cage was tipped to one side by attach-
ing a metal spring to one side of the cage to the cage rack for a 
24-hour period. Control rats were not exposed to the stressors 
but were handled each day at the same time.
Sucrose Preference
Sucrose preference was performed during the final 3  days of 
induction of social defeat stress (days 8–10) using a procedure 
based on that of D’Aquila et al. (1997). Animals were given 2 bot-
tles on their cages between 7:00 pm and 9:00 pm on each day 
that it was performed (the first 2 h of the dark cycle) with 1 bot-
tle containing tap water and the other containing 0.8% sucrose. 
Amounts of sucrose consumed were calculated as percentages 
of the total amount of fluid consumed during the 2-hour period 
on each of the 3 days of testing. The position of the sucrose bot-
tle (left or right) was alternated equally between groups and 
over days. The preference of sucrose over water was used as a 
measure of an animal’s sensitivity to reward and expressed as 
a percent.
Social Interaction Test
The social interaction test was performed 24 hours after the last 
social defeat stress on day 11 of behavioral testing. The interac-
tion test was conducted exactly as previously described (Brown 
et al., 2011). Animals were placed into a locomotor arena that was 
divided in half by a removable metal wire divider. The intruder 
was first placed into the area on one side of the divider and 
allowed to habituate for 5 minutes. After this period, a resident 
rat was placed on the other side of the divider. The amount of 
time spent in a defined interaction zone close to the metal divider 
was measured using ANY-maze video tracking (Stoelting Co).
Porsolt Swim Test
Different groups of animals were tested in the Porsolt swim test. 
Rats were treated using the same drug treatment regimen as 
with the SDS/CUS paradigm, except as noted in the combined 
drug treatments as noted in the Results. On day 8 of drug treat-
ment, all animals began behavioral testing in the Porsolt swim 
test, also known as the forced swim stress test. All animals were 
tested in black cylinders measuring 36  cm in diameter, and 
these cylinders were filled with 23oC to 25oC water following pro-
cedures as reviewed previously (Bogdanova et al., 2013), consist-
ent with the original procedure of Porsolt and coworkers (Porsolt 
et al., 1978). All animals were given a pre-swim exposure test on 
the first day of testing, 24 hours before the swim test session the 
following day. On the first day of testing, animals were exposed 
to the water for 15 minutes, and on the second day were given a 
5-minute trial. The 2 dependent measures used for forced swim 
stress were the latency to first immobility episode (immobil-
ity lasting >5 seconds) and the total immobility time over the 
5-minute period, both recorded on the second day of testing. All 
movements of the animal were recorded by behavioral scanning 
software (ANY-maze, Stoelting Co).
Drug Administration
All drugs used in the study, 3-aminobenzamide (product no. 
A0788; 3-AB), 5-AIQ hydrochloride (product no. A7479), and fluox-
etine (product no. F132), were obtained from Sigma-Aldrich, Inc.
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Statistical Analysis
A Grubb’s test was used to remove statistical outliers from each 
dataset prior to analyses. Statistical analyses were otherwise 
performed as indicated using IBM SPSS Statistics (version 23.0), 
and data were graphed using GraphPad Prism (version 5.0b, 
GraphPad Software). An independent sample t test was used to 
analyze data generated when only 2 groups were analyzed. An 
ANOVA was used to test multiple group comparisons. For post-
hoc statistical comparisons, a Bonferroni correction was applied 
(as noted) to limit Type I error in multiple posthoc comparisons. 
For the combined drug treatment experiment, ANOVA was fol-
lowed by a Dunnett’s Multiple Comparison test that focused 
comparisons of drug treatment groups with the vehicle control 
group. All data are expressed as mean ± SEM.
Results
PARP Inhibitors and the Porsolt Swim Test
An initial preliminary experiment was conducted to examine 
the effects of 3-AB in the Porsolt swim test. Two groups of rats 
received either saline vehicle or 3-AB (40 mg/kg) s.c. daily for 10 
days prior to swim testing. On the 10th day of treatment and 
2 hours after drug or vehicle injections, rats treated with 3-AB 
demonstrated a significantly decreased time spent immobile 
compared with saline-treated controls on day 2 of the swim 
test (t[14] =  2.36, P < .05) (Figure 1A). Additionally, 3-AB-treated rats 
demonstrated a significant increase in the latency to immobility 
(t[13]  = 5.56, P < .001) (Figure 1B).
Based on these data, a more extensive experiment was con-
ducted to examine the effect of PARP inhibitors in the Porsolt 
swim test. Three doses of 3-AB (0.4, 4, and 40 mg/kg) were 
selected for study that were in the approximate range of doses 
shown to be effective in other disease models (Besson et al., 
2003; Zaffini et al., 2016). In addition, a second PARP inhibitor, 
5-AIQ, was tested at a dose of 0.3 mg/kg i.p., a dose previously 
shown to have protective properties in a rat model of myocar-
dial infarction (Wayman et al., 2001). These treatments, and an 
additional group of rats treated with saline vehicle, were admin-
istered once daily for 10 days prior to behavioral testing. Two 
additional treatment groups were analyzed, including fluox-
etine (10 mg/kg i.p.) and 3-AB (40 mg/kg s.c.; denoted 3-AB x 
3), both groups of which received injections 23.5, 5, and 1 hour 
before behavioral testing identical to the protocol followed by 
Lucki and colleagues (1998). A 1-way ANOVA of immobility time 
in the swim test revealed a significant main effect of treatment 
group (F[6,68] = 5.55, P < .001). A posthoc Bonferroni comparison of 
the treatment groups of 5-AIQ, 3-AB 40/mg/kg (for 10 days), 3-AB 
x 3, and fluoxetine was equivalent with respect to immobility 
times, and rats in these groups spent significantly less time 
immobile than rats in the vehicle group and in the rats treated 
with the 2 lower doses of 3-AB (0.4 and 4 mg/kg) (Figure 2A). For 
latency to immobility, 1-way ANOVA revealed a significant main 
effect of group (F[6,68] =  9.08, P < .001) (Figure 2B). Posthoc analysis 
revealed that latencies of the fluoxetine group and rats treated 
with 40 mg/kg 3-AB for 10 days were equivalent and significantly 
greater than all vehicle-treated control rats. The 2 lower dose 
3-AB groups, the 3-AB x 3, the 5-AIQ treated group, and the vehi-
cle control group did not significantly differ from one another. 
The statistical results of all group comparisons are shown in 
Supplemental Table 1.
A third experiment was performed to determine whether 
3-AB would increase the antidepressant activity of fluoxetine, 
again using the Porsolt swim test. Rats were treated with a dose of 
3-AB (4 mg/kg; administered 3 times over 24 hours) that was not 
observed in previous experiments to produce a significant effect 
on immobility time or latency to immobility (see Figure 2A-B). 
A dose of fluoxetine (2.5 mg/kg; administered 3 times over 24 
hours) was chosen that was expected to produce a less than 
maximal antidepressant response in the swim test (Broom et al., 
2002). Both drugs were also administered together at the same 
doses and treatment schedule, as was saline vehicle. Analysis 
of data from this experiment revealed a significant group main 
effect on both immobility time (F = 4.32[3,31], P = .01; Figure 3A) and 
latency to immobility (F = 5.20[3,32], P = .006; Figure 3B). A Dunnett’s 
test was used to compare each drug treatment group to the 
vehicle-treated group. Both 3-AB and fluoxetine alone did not 
significantly affect either immobility time or latency, while the 
combined treatment significantly reduced immobility (P < .01) 
and significantly increased latency to immobility (P < .01).
Drugs that increase locomotor activity can produce false 
positives in the Porsolt swim test. To consider the possibility 
that PARP inhibitors stimulate locomotor activity, 2 measures of 
activity were assessed for all rats of the second and third Porsolt 
swim experiments. Swim speed was assessed during the Porsolt 
swim procedure. Locomotor activity was measured in an open 
field 24 hours after the second day of the Porsolt swim test, at 
the same time after drug or vehicle injections as was performed 
for the swim test. There were no significant group differences 
in swim speed during the Porsolt swim test (F[6,67] =  1.57, P = .170; 
Figure 4A) or in locomotor activity tested the following day 
(F[6,67] = 0.956, P = .463; Figure 4B) in the second experiment (cor-
responding to Figure 2). Likewise, no significant group differ-
ences in swim speed (F[3,31] = 0.487, P = .69; Figure 4C) or locomotor 
activity (F[3,31] = 1.03, P = .37; Figure 4D) were observed in the third 
experiment (corresponding to Figure 3).
Figure 1. Preliminary experiment examining the effects of 3-aminobenzamide (3-AB) in the Porsolt swim test. 3-AB (40 mg/kg; n = 8) or vehicle (n = 10) was administered 
s.c. daily for 10 days prior to the swim test. Swim test data were collected on the 10th day of treatment, 2 hours after drug or vehicle injection. Total time spent immobile 
in the tank (A) and the latency time to immobility (B) were measured. The asterisks indicate statistical significance (*P < .05, **P < .001).
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PARP Inhibitors and Combined and Repeated Social 
Defeat and Unpredictable Stress
Experiments were performed to determine whether the PARP 
inhibitor 3-AB would block the behavioral effects of repeated 
psychological stress. Rats were treated with vehicle, fluoxe-
tine (10 mg/kg i.p. daily), or 3-AB (40 mg/kg s.c. daily) 2 hours 
prior to the social defeat procedure each day for 10 days. These 
rats were also exposed daily to an unpredictable stressor. Rats 
receiving vehicle but no exposure to the 2 daily stressors served 
as a control group. ANOVA revealed a significant main effect of 
group (F[3,28] = 12.91, P = 2.7 x 10
–5) (Figure 5A) on sucrose preference. 
Posthoc analysis showed that vehicle-treated stressed rats had 
a robust reduction in sucrose preference relative to nonstressed 
control rats (P = 1.1 x 10
–5). Sucrose preference was significantly 
higher in stressed rats treated with 3-AB (P = .024) or fluoxetine 
(P = .005) compared with stressed rats treated with vehicle, while 
3-AB and fluoxetine groups did not significantly differ. There 
was also a significant group main effect on time spent in the 
interaction zone (F[3,29] = 3.23, P = .03) (Figure 5B). Vehicle-treated 
rats exposed to the stressors had a robust reduction of time 
in the interaction zone compared with control rats (P = .008). 
Rats treated with 3-AB and exposed to stressors exhibited 
significantly greater interaction times compared with vehicle-
treated rats exposed to stressors (P = .014). Interaction times of 
the fluoxetine-treated rats appeared to be greater than that of 
vehicle-treated rats exposed to stress, although this difference 
did not reach statistical significance (P = .073). The statistical 
results of all group comparisons of sucrose preference and inter-
action times are shown in Supplemental Table 2.
Discussion
The present study is the first to demonstrate the ability of PARP 
inhibitors to counteract the deleterious effects of psychologi-
cal stress on rodent behaviors and to produce antidepressant-
like activity. Two structurally different PARP inhibitors, 3-AB 
and 5-AIQ, demonstrated antidepressant-like activity in the 
Porsolt swim test. Both 3-AB and 5-AIQ produced their antide-
pressant-like responses in the swim test at doses that did not 
significantly affect locomotor activity or swim speed, suggest-
ing that reduced immobility produced by these drugs was not 
secondary to a stimulant effect of the compounds. In addition, 
the combination of 3-AB plus fluoxetine produces antidepres-
sant-like effects in the swim test at doses that did not produce 
a significant effect for either drug when administered alone, 
Figure 2. Effect of poly(ADP-ribose) polymerase (PARP) inhibitors on immobility time (A) and latency to immobility (B) in the Porsolt swim test. Rats were treated daily 
for 10 days prior to the swim test with either saline (vehicle i.p.: n=13), 3-aminobenzamide (3-AB) administered at 3 different doses as noted (s.c.; n=8-10), or 5-AIQ (0.3 
mg/kg i.p.; n=9). Additional groups of rats were administered 3  injections over 24 hours prior to the swim test with either fluoxetine (10 mg/kg i.p. per injection; n = 10; 
FLX x 3) or 3-AB (40 mg/kg s.c. per injection; n = 7; 3-AB x 3). The swim test data were collected 2 h after the final drug or vehicle injection. Asterisks indicate significant 
differences compared to the vehicle group (*P < .05, **P < .01). The results of statistical analyses of all other comparisons can be found in Supplemental Table 1.
Figure 3. Effect of combined treatment of 3-aminobenzamide (3-AB) and fluoxetine (FLX) on immobility time (A) and latency to immobility (B) in the Porsolt swim 
test. Rats were administered 3  injections over 24 hours prior to the swim test with either vehicle (i.p.; n=11), 3-AB (4 mg/kg s.c.; n = 7), FLX (2.5 mg/kg i.p.; n = 7), or 3-AB 
(4 mg/kg s.c.) plus FLX (2.5 mg/kg i.p.; n = 6–7). The swim test data were collected 2 h after the final drug or vehicle injection. Asterisks indicate significant differences 
comparing each drug-treated group with the vehicle group (*P < .01).
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suggesting that combination therapy is a reasonable possibility. 
Finally, 3-AB protected rats from the development of anhedo-
nia and deficits in social interaction following repeated expo-
sure to psychological stressors. These intriguing findings open 
the door to the potential development of a truly novel class of 
antidepressant drugs.
PARP1 is a key nuclear enzyme of the DNA base excision 
repair apparatus that is activated by double- or single-strand 
breaks, such as can occur secondary to oxidative attack of 
nucleotides by free radicals. PARP1 is a member of a subfam-
ily of 3 PARPs (PARP1, PARP2, and PARP3) that covalently build 
PAR polymers onto many different proteins as a mechanism to 
Figure 4. Swim speeds (A and C) and locomotor activities (B and D) of swim test rats. A and B are data from rats of treatment groups studied in Figure 2; C and D are 
data from rats of treatment groups studied in Figure 3. Swim speed was measured during the swim test, and locomotor activity was measured 24 hours after the second 
day of the Porsolt swim test, both of which were measured 2 hours after drug or vehicle injection. There were no significant group effects observed for swim speed or 
locomotor activity in either experiment. Sample sizes are as noted in Figures 2 and 3.
Figure 5. Effect of 3-aminobenzamide (3-AB) on sucrose preference (A) and interaction time (B) in rats exposed to repeated psychological stressors. Treatment groups 
included handled control rats not exposed to stressors (Control; n = 7) and rats exposed to stressors and administered once daily injections of saline vehicle (i.p.; 
Veh-Stressed; n = 7), fluoxetine (10 mg/kg i.p.; n=8), or 3-AB (40 mg/kg s.c.; n = 7). Stressed rats were exposed to social defeat and unpredictable stress each day for 10 
days. Statistical results of specific group comparisons are indicated by horizontal lines above bars, with asterisks indicating significance (*P < .05, **P < .01, ***P < .0001). 
Statistical results of all comparisons are provided in Supplemental Table 2.
Downloaded from https://academic.oup.com/ijnp/article-abstract/20/12/994/4061570
by Medical Library James H. Quillen College of Medicine user
on 27 August 2018
1000 | International Journal of Neuropsychopharmacology, 2017
regulate a variety of cellular functions. PARP1 is expressed in 
many mammalian brain regions, and its gene expression in the 
brain appears to be highest among the PARP1, PARP2, and PARP3 
enzymes (2010 Allen Institute for Brain Science, Allen Mouse 
Brain Atlas, available from http://mouse.brain-map.org). PAR 
polymers are bulky and charged, and addition of PAR polymers 
to nuclear proteins by PARP1 can modify protein-protein and 
protein-DNA interactions. Target proteins of PARP1-mediated 
PARylation include itself, histones, and transcription factors 
resulting in chromatin remodeling and regulation of gene 
transcription. DNA damage repair is facilitated by PARP1, but 
PARP1 also facilitates NF-κB-mediated inflammatory responses 
(Martínez-Zamudio and Ha, 2014), and PARP1 can directly bind 
to promoter regions as a transcription factor (Ambrose et  al., 
2007). Under conditions of excessive PARP1 activation, cell death 
can ensue due to depletion of cellular NAD+, the substrate of 
PARylation (Berger, 1985). Recent studies demonstrate that 
PARP1 also has PARylation-independent effects on gene expres-
sion of inflammatory mediators (Ha et al., 2002), and it can be 
activated by TNFα independently from DNA damage (Vuong 
et al., 2015).
Drugs that inhibit PARP have therapeutic potential in a num-
ber of different conditions. The anti-cancer properties of PARP 
inhibitors are well known. Since cancer cells exploit PARP1 
to protect themselves from death secondary to DNA lesions, 
PARP1 inhibitors facilitate the anti-cancer effects of DNA dam-
aging anti-cancer drugs (e.g., cisplatin) and radiation therapy. 
Numerous PARP1 inhibitors are in clinical trials for cancer and 
one is currently marketed (olaparib, Astra-Zeneca, Inc.). With 
regards to the ability of PARP1 to facilitate NF-κB activation, 
PARP inhibitors have been recently demonstrated to have anti-
inflammatory and neuroprotective actions in a number of differ-
ent conditions associated with inflammation, including chronic 
asthma (Zaffini et  al., 2016), myocardial infarction (Wayman 
et al., 2001), stress-evoked immunocompromise (Drazen et al., 
2001), traumatic brain injury (Besson et al., 2003), and cerebral 
ischemia (Gerace et al., 2012). In the context of the antiinflam-
matory effects of PARP inhibitors, there has been a recent 
reemergence of interest in the role of inflammation in depres-
sive disorders, although this continues to be a matter of debate 
(Mechawar and Savitz, 2016). Elevated expression of inflamma-
tory cytokines, IL1β and TNFα, has been observed in human 
MDD patients and/or suicide victims (Shelton et al., 2011; Pandey 
et al., 2012; Rizavi et al., 2016). Interestingly, inhibition of PARP1 
blocks immune stimulation-induced increases in TNFα and IL1β 
(Hassa and Hottiger, 2002). Although the poor affinity of 3-AB 
for PARP-1 has precluded its use as a cancer therapy (Calvert 
and Azzariti, 2011), its putative efficacy for treating depressive 
symptoms demonstrated here suggests action through a differ-
ent mechanism in which lower affinity is functional and possi-
bly preferable. Hence, it seems possible that the ability of PARP1 
inhibitors to produce antidepressant-like effects in rodents is 
related to the antiinflammatory effects of these drugs, although 
other possible mechanisms may be at work as well.
PARP1 is activated under conditions of elevated oxidative 
stress (Liu et al., 2000; Lan et al., 2003; Adaikalakoteswari et 
al., 2007), and numerous studies suggest that MDD is associ-
ated with elevated oxidative stress (Maes et al., 2011; Maurya 
et al., 2016). Likewise, rodents exposed to psychological stress 
demonstrate oxidative stress conditions in the brain (Che et al., 
2015; Mejia-Carmona et al., 2015; Réus et al., 2015). Because oli-
godendrocytes are highly sensitive to oxidative stress (Kim and 
Kim, 1991; Connor and Menzies, 1996; Thorburne and Juurlink, 
1996; Juurlink et al., 1998), they can be viewed as a “canary in the 
coal mine” for detecting oxidative stress conditions in the brain. 
Recently, Szebeni et al. (2014, 2016) studied indices of oxidative 
stress in oligodendrocytes laser captured from psychiatrically 
normal and MDD brain donors. This research demonstrated 
elevated levels of DNA oxidation, shortened telomeres, reduced 
gene expression of antioxidant enzymes, and elevated gene 
expression of PARP1 in prefrontal cortical white matter from 
MDD brain donors compared with matched normal control 
donors. Although PARP1 protein and activity were not measured 
in that study, others have shown that PARP1 gene expression is 
upregulated under oxidative stress conditions in tandem with 
PARP activity levels (Adaikalakoteswari et al., 2007). Hence, these 
data draw attention to the possibility that PARP1 upregulation in 
MDD may contribute to cellular demise that contributes mecha-
nistically to behavioral sequelae related to the disorder. The 
ability of PARP inhibitors to produce antidepressant-like actions 
in rodent behavioral models in the present study further sup-
ports the role of PARP1 in depression pathophysiology.
The rodent model of repeated stress in this study is rather 
unique in that 2 stressors were administered as we have pre-
viously reported (Szebeni et  al., 2016). The rationale for using 
this double stress model was to reduce the likelihood of stress 
resilience. Nestler and colleagues have constructed a theory of 
a “neurobiology of resilience” that occurs in both rodents and 
humans, wherein the rodent may be more well adapted to 
develop resilience to stressors evolutionarily (Krishnan et  al., 
2007; Russo et  al., 2012). Since SDS is typically performed at 
the same time each day, the rodent can predict over time when 
the stressor will occur, possibly enhancing resilience. Humans 
rarely experience stressors at the same time each day, a fact that 
weakens the construct validity of SDS. We suggest that the com-
bination of a mild (Riaz et  al., 2015) stressor of unpredictable 
nature (CUS) to the paradigm of SDS improves construct valid-
ity and presumably minimizes the likelihood of rats to demon-
strate resilience.
PARP inhibitors have been shown to interfere with the 
formation of long-term potentiation (LTP) and can disrupt 
long-term memory formation in Aplysia bathed in inhibi-
tors (Cohen-Armon et al., 2004) and in mice when inhibitors 
are infused into the cerebral ventricles (Goldberg et al., 2009). 
PARP knockout mice also demonstrate defects in LTP forma-
tion (Visochek et  al., 2016). It is difficult to compare the lev-
els of PARP inhibition in these studies with those achieved by 
doses of PARP inhibitors administered subcutaneously or intra-
peritoneally to rats in the present study. It is noted that PARP 
inhibitors (olaparib and niraparib) are currently FDA approved 
for the treatment of specific cancers, and at the current time 
reports of disruption of memory in humans taking these medi-
cations is absent in the published literature. Rather, there is 
growing interest in PARP1 as a therapeutic target for the treat-
ment of Alzheimer’s disease (Abeti et al., 2011; Martire et al., 
2015; Wang et al., 2015). The combined SDS/CUS model used 
in the present study is likely to have a memory component 
associated with it such that pretreatment with PARP inhibitors 
could interfere with the formation of the memory of stressful 
events in the model. Moreover, forced swim-induced behav-
ioral despair (increased immobility time) requires the forma-
tion of LTP in the hippocampus (Jing et al., 2015), effects that 
are blocked by NMDA receptor antagonists (ketamine, MK-801) 
with known antidepressant activity (Berman et al., 2000; Trullas 
and Skolnick, 1990). In fact, suppression of hippocampal LTP 
has been observed following treatment of rats with several 
antidepressant drugs, including trimipramine (Massicotte et al. 
1993), fluoxetine (Shakesby et al., 2002; Stewart and Reid, 2000; 
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Rubio et al., 2013), fluvoxamine (Kojima et al., 2003), escitalo-
pram (Mnie-Filali et al., 2006), and milnacipram (Tachibana et 
al., 2004). Hence, the potential role of LTP inhibition in mediat-
ing possible memory-disrupting effects or antidepressant-like 
activity of PARP inhibitors in rats warrants further study. In 
addition, direct effects of 3-AB or 5-AIQ on monoamine recep-
tors or transporters have not been described. Although neither 
3-AB nor 5-AIQ are catecholamine like or tryptamine like, an 
exploration of potential secondary effects of these drugs on 
biological amines will be important to clarify the mechanism 
of their antidepressant-like activity.
Inadequate or incomplete treatment of MDD using cur-
rently available antidepressant drugs is a major health and 
economic issue (Thase, 2009). Unfortunately, antidepressants 
that are newer to the market have not substantially mitigated 
this problem, because these new drugs do not demonstrate a 
significantly greater therapeutic efficacy than older drugs, with 
minor exceptions (Montgomery et al., 2007; Papakostas et al., 
2007). Given therapeutic shortcomings of current antidepres-
sants, it is imperative that novel drug targets be identified to 
improve the efficacy of existing antidepressants through adju-
vant treatments or provide therapeutic alternatives to the 
many who do not respond. The use of ketamine represents the 
first noteworthy recent advance in the field, although some 
major concerns remain about its efficacy (Murrough, 2016), 
side effects, and its potential for diversion (Sassano-Higgins 
et  al., 2016). The primary actions of current commonly pre-
scribed antidepressants involve modulation of the transmis-
sion of noradrenergic and serotonergic neurons. The present 
study demonstrates antidepressant-like behavioral effects of 
PARP inhibitors in 2 different animal models used typically 
to screen drugs for antidepressant activity in humans. Given 
that PARP inhibitors have no known direct effects on brain 
norepinephrine or serotonin, the findings here strongly impli-
cate PARP inhibitors as an entirely novel type of antidepres-
sant. Results here also suggest that PARP inhibitors could be 
used as an adjuvant to existing antidepressant treatments. The 
potential use of PARP inhibitors as antidepressants in humans 
will require that adequate safety testing is completed, par-
ticularly focusing on potential toxicities of these compounds 
that could result from interfering with the multiple cellular 
systems that are impacted by these drugs (Passeri et al., 2016). 
The mechanisms involved in antidepressant-like effects of the 
PARP inhibitors that were tested are presumed to be mediated 
primarily through inhibition of PARP. The role of secondary 
effects of PARP inhibitors in antidepressant actions, for exam-
ple, suppression of LTP, antiinflammatory effects, protection 
from oxidative stress-induced NAD+ depletion, and potential 
effects on monoamine or glutamate transmitters, remain to be 
determined.
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